<SEC-DOCUMENT>0001193125-24-231214.txt : 20241002
<SEC-HEADER>0001193125-24-231214.hdr.sgml : 20241002
<ACCEPTANCE-DATETIME>20241002165711
ACCESSION NUMBER:		0001193125-24-231214
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20241002
DATE AS OF CHANGE:		20241002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280447
		FILM NUMBER:		241348476

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d848734d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280447</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
June&nbsp;24, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,100,000 American Depositary Shares representing 11,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g848734g1002082652732.jpg" ALT="LOGO" STYLE="width:2.25139in;height:0.646528in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June&nbsp;24, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280447),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on October&nbsp;2, 2024 (the &#147;October 2, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached
the October&nbsp;2, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and
supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in
conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On October&nbsp;2, 2024, the last reported sale price
of the ADSs on Nasdaq was $0.4364 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is October&nbsp;2, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia Therapeutics
Announces Presentation of Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology
66th Annual Meeting&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration
statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated October&nbsp;2, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited </B>(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 2&nbsp;October 2024</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g848734kazia.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2&nbsp;October 2024 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor
Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>Annual Meeting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Over <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the patients at maximum tolerated dose (MTD) achieved intracranial response which
compares favorably to historical response rates for whole brain radiation therapy alone </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, October&nbsp;2, 2024&nbsp;&#150; Kazia Therapeutics
Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain
metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Annual Meeting (ASTRO 2024), which is taking place from
September 29&nbsp;- October 2, 2024, in Washington, D.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The encouraging response rates observed from this Phase 1 study suggests that the
concurrent administration of the investigational brain penetrant PI3K inhibitor, paxalisib, in combination radiation therapy appears to be a viable treatment approach for addressing the tumor radioresistance in patients harboring PI3K pathway
mutations,&#148; said John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. &#147;Additional data, including circulating tumor DNA (ctDNA) from this study will be presented at an upcoming 2024 scientific congress and discussions for a
potential pivotal registration study to evaluate this unique combination therapy for patients with PI3K mutant brain metastases are ongoing.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation details: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenter:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brandon S. Imber, M.D., M.A., Memorial Sloan Kettering Cancer Center</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Abstract</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1094</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Scientific&nbsp;Session&nbsp;Title:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CNS 4:&nbsp;Brain&nbsp;Mets&nbsp;and&nbsp;LMD</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Session Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;1, <FONT STYLE="white-space:nowrap">5:15-6:15</FONT> PM ET</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Results from Part II of Phase 1 Study </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Concurrent daily administration of paxalisib with brain radiotherapy was generally well-tolerated at a maximum
dose of 45 mg per day<B> </B>in advanced solid tumor patients with brain metastases and PI3K pathway mutations; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g848734kazia.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The most commonly reported adverse events in the study were nausea, vomiting and hyperglycemia;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Established <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-principle</FONT></FONT>
for molecularly-selected, rational combination studies in radiation oncology to assess safety and ultimately efficacy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment with 45mg paxalisib and radiotherapy demonstrated a 67% PR; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the patients at MTD achieved intracranial response
which compares favorably to historical response rates for WBRT alone. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1 study (n=17 evaluable) was a <FONT
STYLE="white-space:nowrap">two-part,</FONT> investigator-initiated trial evaluating the use of paxalisib with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors. Part I of the study
established the MTD of paxalisib in combination with radiation therapy, while also demonstrating promising signs of clinical activity in all nine evaluable patients. Part II was a <FONT STYLE="white-space:nowrap">follow-on</FONT> expansion cohort to
further evaluate safety and efficacy of the MTD (45mg daily) combined with radiation therapy in up to 12 additional patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 200,000
cancer patients develop brain metastases in the United States each year. Radiotherapy is the mainstay of treatment for brain metastases, and generally consists of either stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) or some
combination thereof. The efficacy in patients who receive WBRT differs according to the type of tumor and the number and volume of brain metastases, but several recent publications cite overall response rates of
<FONT STYLE="white-space:nowrap">20-45%.</FONT> The increasing incidence of brain metastasis and the low response rates to existing treatments underscores the need for new treatment options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, an investigational
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A
completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major medical
conference. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in
August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation
and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g848734kazia.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule
inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been
completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an
investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia&#146;s current expectations and projections
about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and
uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in
Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this
announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g848734g1002082652732.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g848734g1002082652732.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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B0&(Z$U/31P.*7-26E96%HI,T9H&+129HS0 M%)FB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g848734kazia.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g848734kazia.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MUORL<7=>/_#*>']?\1:7J=IKMMX=MKB>^ATFZAN)1) KE(3M8B,2,A"R-\A
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M6_)5I24X.SLTFKZQ:::W35FDS1K$Z@H * "@ H * "@ H * "@ H * "@ H
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MH^3XUS?,\BR#$9AE&'5?%4YTHMR@YQI4YRM.JX1:<N72*UM%R4I)QBT<_P"
M-6&H>#I_B;XC\*6%KXEAT[5)Y]0L-,B@U/6=,TZW:6*>#<IE#7$,'E*I<A_)
M4KB-T5:XG<<IKXK+,'CJ^)RS"+VJH.HYQIU%%RG344U!SB[ZJ*:;L_>38< T
MZO$E#+,VS'*\+E^>YG4CAOK7L8TI5*4ZD:=.K*<DZD:<E;FO)IQAS1M!Q2\+
MTW^Q_P!L/26DUBVU3P1>^ =3VP-IMU%JUG?V/B&)&DC8W5I;@7J?V.H)"D1A
MT;#B?9'^5TU0XOHWJQJ8*> J:<DE.,HU%JG>,?>M#73W?-.Q_5^*>9> ^8*&
M KX7B"CQ'ADYJM3G0J4:N#G)1=J=6;]FWB&U=_O+./NN',_I:[^$GP^U#4/"
M^L:GX>@U+5_!]EINGZ'J5W<7AN(;?2,-8"ZCAN(X-0:&4&53<Q2A7=F4#-?2
M2RK 3J8:K4PZG6P<81I3DY<R4/AO9I2L]?>3UU/R2AQGQ+@\)F^ P>:3PF!S
MRI6JXNA3A3Y)SKZ5>1RA*I14HVB_93A>*2;=CQ_QI\-?#WPT\4^*?VBA<ZWJ
M]_I-O=:I#X7C>&&UDU/4;4:'(\E^(I)ET\)>M(R>6WDJ&?+I&(SY&,RW#9=B
ML5Q#>I5J48N:HII1YY1]FVY6;4;2N]/=5WJE8^YR#BS-N*\FR7PK]G@\%A,9
M5IX=X^492J1HTJKQ<4J;G&#J\U/E333JNT/=E-S.X^&WC#2OCEX!C\2:WX-L
M?,LM4U"U32=02'4[4WMA%%)'<6%Q=VR?NY8KF.,L8QM=94)8)D^[PYGF)Q6'
MCC<-4JY;*<I4ING4DO=35_>CR.4;/56^)-=+GP7B7P'@>&LYGD6+^K\04J%&
MEBZ+K4*=U*I&7+&5.3JQIU$XNS4G>G*$M%*RR/@U\0_&_C#7/$6F^)-+@M+#
M2X,H\%A+8_V9?+=) ND.'8[R8#,P5\R+]D.3AJ_0>*<CR?*L'E];+L7*M6Q#
M]Y2J1G[2')S>V7*ER^]RKL^?3X6?A7 7%/$F?9CFV%SC 1PV&P2]V4*,Z/L:
MJJ<GU9\S?,^3FDKWE'D=W9H^AZ^(/U$_ W]MG6W\,_MB77B..V%Y)X>;X;:W
M'9M(8ENGTK3=(OTMC*J.8Q(T 3<%8C=D XQ7TV7QY\O4+\JE[17[7;1\[CY>
MSQO.E?DY)6]+.WX"? +1#^V3^TOJ/B'XQZU:3P0:?+XEN_#44TUDNKV.ES6U
MIIOA30XED+VVBVJW$4EQLF,[00RDNTUS+<QF)E_9^#C3H1M=\JGV;U<F^[Z=
M%\A85?7L7*==JT5?EVNE:T4NRZ]?OT_>RUM;:RMK>RLX(;2TM((K6UM;>-(;
M>VMK>-8H(((HP%BACB145% "JH &!7S+>OF?1I622T2V1/0!^$?[77BS7_VE
MOVD+7X7_  YC;7;;P5#JOAG0+2!MD%YKEC;3ZKXTU!)'XPDFF?8A)]R1=#C>
M,D2AF^DP,(8+!NO6]WGM)]^5NT%^OSU/GL;.6+Q2H4O>]G=)=+I-R?RM;Y:'
MT5_P36^,*7FA>(_@AK=RR:GX>N+GQ-X2@G#*[Z/>SJOB'3(\@!&LM7ECNQ&?
MG;^V+DCY;=MO)F]#EG'$07N2M%OS2T?S7Y'5E5=<DL.W:5-MQ7E?5?)_F?JE
M7C'KG/\ BC5] \,Z!K'BCQ(]K;:-X=TN^U?4KRYB206MAI]O)=7+J&4EF\N)
MMJ+R[;54%F JH1E*480OS2:22[O1$SE&G&4Y>[&";;?1+5GXA? +P[K?[7O[
M4^I?$?Q5:1#PKX:U*U\6:Q9+$B6-KIVGS&#P5X1BCC0(ZR26<(FW >?#I^H2
M.QEER_T6)G' 8&%&'QR7*GYO6<K^5[+M='@8:$L;C)5IKW*;4FNEEI"-M>UW
M\S]W:^;/H3\_?^"DW_)O>G?]E)\-_P#IG\35Z>4_[U_VY+\T>=FG^[+_ !Q_
M)GH'[!?_ ":S\./^OCQI_P"ISXCK+,?]\K?]N_\ I*-,O_W.C_V]_P"E2/L*
MN$[3\-OVS?%NN_M$_M&:%\&OAWMUJ/P>]UX7TVUAE$=M<>+9P;SQ==R3-A5B
ML8=.@LY6((C.BW+(2)#N^CR^$<'@YXFK[O/:3T^RM(:>;;:]5U/G\?.6)Q4,
M-27,J=TNW-O+_P !5D_F>R_\$VOBZ]LOBKX">(WFM=1TVZO/$WA2VNXWCDB5
M72W\5Z&RR8,$UO=K;WJ0%=Q-QJ3''E8//F]!)T\3#522C)K[XR]&M/DC?*JU
ME/"S]V4&W%>6TEZIZ_-GZR5XA[)X5\<?&?C+P?IV@R^$X"JWUY<Q:A?"P34/
M),26YM+3RI8Y$C^T&2X.XIN/V;"D$G/V'"&593FE?&0S.IR^PIQ=*G[7V7-=
MR4Y\UTW[.T=$[>]=IH_.?$7/\_R#!Y;4R*BY?6*TXUZJH^WY%%0=.GRN,HQ]
MK>?O-7]RT6FQOQ*\9?$/0/@_8^)_#6AF?Q=/::"^I6::=+?-I27L"/J5TNEK
MEW,,I6,QN'$0F+2 B)J^$XHJ5<NCC_['7UI4<1*G2E;VG[E5)152T?B]U+5:
M:\UK:'[9X59?E7$F99)0XPKK*:.*P<:U>#J+#KZW[&$_J[JS_@IS<M&U*\53
M4E*29U/P=EU"[^'?AS4]9\.6'A?6]4MI+W5=.T_3(M(C>X:YFCAOY;"*-/(N
M+NSCM[AE894SXX  &&4NI++\/4K8>.&KU(\TX1@J:YKNTG%)<KDDI-/57L;\
M<4\+A^)\UP>7YK6SC+L%45+#8BM7EB&J:C&4J4:LI2YH4:DITHRB^62CS*][
MOX>\;>-O&ESXQUBYO-:U>RO+#5KRWM;:WN[FSCTR.UNI(X;>V@A=%B"(B@L%
MW.1O<LS$G^D\FR7)X91A(4L'1K4Z]"G*<YPC.564X)RE*33>K;LD_=6D;)'\
M*\2\2<23XAS"I7S+%82KA,55ITJ=.K.E"A&G4E&$80BXI645=M7GO)R;;?WM
MX OK_P 1> O#U[XBB2XO-3TA#?I<01[+R.3S(TEF@*",K<VPCD9=@4^<<#!Q
M7XEGN&PN%S;,<+A4I86E5E"$;\R2ZPN[W46W#7MJ?U!PGC\PQ>09+F&-E*GF
M%2A3JRFOW<^=/W*JY;<LI14:GN\MF[I+1+Q?X#^+OB=J_B7QCX?\6^#[?PSX
M9T,S_P!CI:: VAV>GW?]I-&NE63I&D.I0/;&:<S('.8U<OMN%S\-D>+S.MB<
M9A\7@XX7#4')4N6DZ2BU*W)'9333<N9+SO:2/WKQ%R3A# 93P_F>1Y]4S?-\
MPC!XOVF+6*J5(>P3=>HFW4H3C42IJG-K1N"BG2D:NA>-_B3=_&/4/#%[IK)X
M6@NM5B\HZ8L45OIEM%.=-U5=2\K?*]P\=KPTK(QN2BJI *?KN,RC(:/"N'S"
MCB5+,I1I-_O;R=232JT?8\WNJ"YG?EYK03<FG8_D_+>(>+:_'N+R?$X-QR6E
M/$)+V')&%"$9>PQ"KN-YRJM0TYW%^T<5%.*:^C*^'/U,_"O]JY5?]NS14=59
M&\0_!Y61@&5E9= #*RD8*D$@@U]'@G;+)=+1J_J>!C/^1A#UI?FC6_:W^"?B
M+]F?XGZ1\>/@^_\ PCWAG4M<CN+)=*CVQ^#_ !3)!*]WIDEFT9@_X1W5(5O&
MB@.Z#;)=V+Q)"(%FG 5X8NC+"U_>G&-M?M16S7]Z/??9]&&-P\\)66)P_NQD
MUHE\,NS7\LOSNNJ/U%_9U^.WA_X_?#RP\5:6T=KKEBL&F^,-"!(ET77UMT>=
M8U8EI-+N?FGM+C)#Q$HQ$T$T<?CXK#3PE5TWK%ZQEWC_ )K9KHSU\+B(XBDI
MQT:TE'LU^G5/L-_:8^+5O\%O@WXN\8"Y2#7'L9-#\(QG:9)_%.KPRV^EM%&_
M$PM,3:A*G>'39N^,F$H>WKTZ=O=O>7E%:OTOLO-H,566'H3J7LTK1_Q/;[M_
M1'XB_ 'X:_M522?\+<^!?A[4)9;@ZKHB>*O/\$R22N\L+:LEO#XQNBQD:4+&
M]W%!DGSHA*<RJ?HL36P*_<8F27+9\OOJW;X%]R/ PM+&*U?#0O>ZYO=^>DG^
M)#(WQM_9B^.7A+XH?$OPW=:+XDU#6KOQ1>VZ2^'T@\3Z9?74MKXKM8AX:GDT
M^T>ZM[R[C,2I'Y+W4,PB V$MO#8S"SH49*48I15[^ZTO<^)7TLM?47^T8/$0
MK58<LY2<G:WO+:2M%M)Z_J?T2:!KFF^)M"T;Q'HUPMWI&O:5I^LZ7<K@"XT_
M4[6*\LY@ 3C=;S1G&>,X[5\K*+A*4)*SBVFO-:,^FC)2C&47>,DFGY/5'YB_
M\%*OC*=+T#P]\%=$O62]\0M%XF\8+!( R:%8S.FAZ7<!2?EO-4AEO&0[2!H]
MN>4FY]C)\.G.6(DM(>["_P#-I=_):?/R/)S6NXPCAX;RLY?X5LOF_P O,\(_
M92_:W^#W[.WP[N?#^H^#?'&J>+-=UBYU?Q+J^E6WA\VDXBS:Z/8VLEYKL$[V
MMK8+OQ)%'B>]NRHVN">C&X'$8FMS*I"-."2BFY:=7M'=O\$C#!8W#X6CR^SF
MYR;<FE'T2UDME^-S]GO WBVP\>^#/"OC;2[>[M--\6^'M(\1V%K?K"E];6FL
M6,%_!!=I;S2Q+<I'.JN(Y9%W*=K$8)\"<'3G*F]X-Q=MM';0]RG-5(0FDTI)
M22>]FKH^)_\ @I-Q^SWIW;_BY/AOV_Y@_B:O0RG3%=K0E^:.'-/]V7^./Y,]
M _8+_P"36?AQ[7'C3\,>.?$=99C_ +Y6_P"W?_24:9=_N='RYO\ TJ1ZW^T'
M\4[3X-?"+QEXZEFBCU&PTR6R\.02;";OQ/J:FRT.!(G_ -<B7DB7,R@,1;VE
MP^,1FL<+0>(KTZ2VD_>\HK67X;>=C;$UEAZ%2KLXKW5_>VBOO/PP^ ?P_P#V
MJ+^ZNOB]\#M!U"[O9;K5M&F\6R2^"9KA[VY%M=:P+=/&=P6,\@N(EDO((<MY
MT\/G'=.E?1XJK@H)8;$224>5J'OZ65E\"_#YVV/G\-3QKO6P\6V[KF?+\])/
M\45=>B^/O[.GQF\*_%WXE^';C1O&&I^(+SQ2)9)?#R6WB<"9(?%%K)_PBT\E
MG:_;;7498+A42)\:CYNPEPQ</JN+P\\-1DG"*4;>]>/\K]Y)Z/U[$R^LX/$4
M\16BXSD[M^[:722]W173/Z(?"OB32_&/AGP_XLT.;S]'\2:-INN:;*=H9K/4
M[2*\@$BJ2$F6.4*Z9RKJRGE37RLX.G.5.2M*#::\UH?3PDIPC..L9)->CU1R
MOQ8U;Q5HG@N^OO!UO-/JZW%I&7M[07UQ9V;R?Z1=0VC1R"9UPB',;A%E:0CY
M,CV^&\-EN+S:A0S2HJ>$:DWS3]G&4TO=C*:<7%;O1IR<5%.\CY7C7&YUEW#^
M*Q.0495<?&5.*<*?MITJ;E:=2%+EFIN*LK.,E&+<VO=TJ> =3\<Z]\.#=:U"
M--\6S6>J0:;<7UJ+4S2K%(FE:E?6(B40 SE"R"-0Z1"15"R@5EQ-A<#A,QQE
M#)JRG0C']V^;GA3J.+]Q3O+GC"5M;M[Q;;5SLX!Q^8XW*LIQG%6$G3JNM'ZQ
M!0]C5K8:%57E[.T?95*E-225HIZ322E9>/\ PI\3^,OACHNLW'[0_BG^RQJV
MM6]OX6CUW4H=5U"1X(ISJ\L+::]TR::6FL-@+!(MCDB-)4,GY[E>)QF64:TN
M(,5[+VM51H*I)3EHGSM.'-[FL;=(ZWLFC^B.,\IR#BW,<!2\+<EGBU@L).>8
M/"8>I0I*\H_5U*-=4[UDHU>9I7J7BDYSC)1^AKWPIX)UZ\L]:O\ 0] U2]FC
MBFL]0GM;2YDNHEC62"19"I%Y&L6QD)\P!<%>*^XP^;YAAL/]7PN85J&&J:J%
M.K*,'=7;BD[:IZN.Y^"8WAS*<7C'BL?DV'KXW"OEE4K8>#J0E!\JC4<HWO"2
MLE/X6K*S1P7C_P =66IVGBGX;^ /%FG6GQ672I!I.EK*UO<I<11QWD]K:WDL
M0M8]1.F)/L7S@\)99'"+&S+\SC\=&K'%9?@<5".:\C<(7M*]N9I2?NJ?*G;W
MDXNTG9*Z_3^&N':^"J9-Q3Q'D>(J\%QQ$5B*ZA>FZ?,Z4)2A&7M'15?D4GR<
MM1)TX.4I).;X(:;\2=(^'Z6WQ*N;B\\3C4-1FM4U#4(M0OH=.98OL5KJ&H0R
MS+-*;A;F0-YLI2*>)"04V)61TL?1P5.&:5'*OSR=W)3G&F[64I)OF:]YK5Z-
M*^AEXB8SA?&<15Z_!N&A0RM8>E%1A3E0HSQ$8RYY4J4XQE3@TX0=X1O.,YI-
M24GSGP<\2?%+6?$/B2V\<6=]#ID$#20->Z4NFI9:D+M$2QL76WC^TP-;/.3E
MYMHMXFW_ +PF3].XIP'#F#P67SR:O">(D[34*SJN=+DO[2HG*7LY*2BDK1OS
M27+[NG\[<!YMQGC\TS>EQ'A:M#!THMTW5PZH*E6]HDJ-&2A'VL'3<FW>=N2+
MYO>][Z(KX<_4CS#7?@M\*/$WBNW\<>(/ /AK5_%UI-IT]OK]]I\<VHQS:0T;
M:9+YQ/S/;&&+RRP.!$HZ* -HUZU.#I0JRC3=[Q3:6N^GF92HTI34Y4XN<;6D
MUKIMKY'9>)/#/A[QCHM]X<\5:-IWB#0=22-+[2=6M8KVQN5BECN(?-@F4J6C
MGBBE1AAD>-64AE!&<92IR4H2<91V:=FBY1C.+A**E%[I['->!_A/\-OAH^HR
M^ ?!7A_PE)JZ6L>IOHMA%9O>QV1G:T2X9.76)KF<J,X!E;UJZE:K5Y?:U)3Y
M=N9WMWM]Q-.C2HW]E3C"^_*K;;;=BUXX^&O@+XE6=EI_CWPIH_BJRTVY>\L+
M;6+47,5I=21&!YX5)&R1H6*$^AI4ZM2BVZ4W!M6;B[:!4I4ZJ2J04U'9-7\O
MR-WPYX;T#PAHMAX<\+Z/IV@:#I<30Z=I.E6L5G8V<;RR3R"&"%0JM)/++*[8
M+/)*[N2SDF92E.3E.3E)[MO7[RHQC3BH0BHQCLDK)?(P/'/PQ^'WQ+MK"T\?
M>#]"\60:7--/IJ:U817;6$MPB1W#6LK / )4CB$BJP5_)C+ F-=M4ZM2BVZ4
MY4V]'RNQ-2E3JI*I",U'9-7.BT#P_HOA71M.\.^'=-M='T/2+9+/3-+L8Q%:
M65K&24@@C'W$!8G'N:F4I2DY2;E*3NV][E1C&G%0@E&,59):))'G/BSX!?!C
MQUKEUXF\7_#;PKX@U^]2VCO-6U'3DEO;E+.WBM+43S!@9/*M8(8E+9(2)%SA
M0!K#$XBE%0IUIPA'9)M(SGAZ%27-.E&4N[6NFQS?_#*?[.0_YHYX'_\ !4O;
M_MI5_7<6O^8B>G]YD?4\*O\ F'AI_=1[AH^D:7X>TG3="T2QMM+T?1[&UTS2
M]-LXUAM+#3[&%+:TM+:)>(X8H(T15'0**YFVVVW=MW;?<Z(Q4$HQ7*HJR2V2
M6B7R,7QGX$\'?$/1U\/^-_#FE^)]%2\@U!--U>V6YMDO;9)HX+I48C;,D<\Z
MA@0<2N.C&JIU*E&7-2FX22M>+L[?(F=.%2/)4BI171JZT+?A7PGX:\#Z%9>&
M/".BV'A[P_IIN#8Z3ID"V]E:F[NIKVY,42]&EN[B>5CR2TK'O2G.<Y.<Y.4G
MNV]=-%^"'"$:45"$5",=DE9+KL9GC?X=>!OB3IUKI'CSPOI'BK3+&]74;.RU
MBV%S!;WR036RW42$C;*+>XGCSZ2L*JG5J4'S4INF[6O%V=NWX"J4J=5*-2"G
M%.Z35U<U?"_A7PWX)T2R\->$M$TWP[H.G"466DZ3:Q6=E;^?-)<3LD,2@>9+
M<2R2NYRSO(S,2S$U,YSG)RG)RD]VW=CA"-.*A"*C&.R2LE\C)\;_  X\!_$F
MPM-,\>^$]$\5V%A=&]LK?6K&*[6TNC$T+36S.-\+M$Q5MC ,,!@=HQ5.K4HM
MNE.5-M6;B[:?(4Z5.JE&I!34=4FKFUX;\-Z#X/T33_#7AC2K/0]!TF)H--TK
M3XA!9V<+S23O'!$/N*TTLKGW<GO4RE*<G*<G*3W;W'&,:<5""48QT26R-NIV
M^16WR/F^WT'XJVGQ@O/$%]J$\/@B*XOIY+B?583HZZ MM(8+0:8;G=#<1A8L
MN8$VR1O,7()+_=5,9PW4X6HX&CAT\Y:II*-*7MO;\ZYINKR6E"2NE'G>CC'E
MNM/RFCEO&M#CO$9GB<7.'#<959.4L1'ZLL(J;Y*2P_M+PJ1:C>?LU:495')I
MZZ'B;PY\)OVC(+:U?6+^\E\)7,LJ2Z0\NEWD,>HB))XV34].9;BRG-C#^\CC
M.UH%VR*20WPG$?"%=0P:SG"5<,GS2HRC.&ND>>#<?:16G+S1=I+1JQ^U^''B
MX\HKYM4X/S#"XUU8TZ>*IUZ%645R.I[&K&,O83O%RJ*,XRE3=VI*6B6'X]_9
M_OO$_C_X?^*=$\3?V)HW@VST/3AI96YDNK.TT"]>Z@.CRH^P2SQ,D,AF*E?*
M5RTH_=K\YCLBGB<?E^*HXGV%'!*G'V?O74:4FX\C3M=W2ES=%N]C]%X:\2L/
MDO"_$^28[)HYACL_J8FM]9;@HRJ8NDJ<_K$7'F<:4DZE-4]&Y2BE3NYOJM4^
M&/PR\'^-=0^-VJRWMAJ<'F3SM)=-+I,-[>VO]E27D&GPVK3R7T\<[)L$DB;Y
MBZQ!L,OLX'ANGC,YAB<'0G6S"NWR04DH<W(U*=G91]R[DY2Y5J]#XS-_%#-<
MOX&GP[F>-H8;AO!1A[2HZ+=?V4:\:M*BYQ<G**K<G)&%/VCM&#E*.AS?Q*G\
M3_$[0?#FJ_"75+J^TN&^OXM4AL+XZ)>+>*MJ+5KD7<UJ^V%3/F,D8^T1R ,K
M!E_2,@AEW#V.QV%XGPL:-=TZ?LO:TUB(<KYG+EY(U(WG[MI+^646TTT_Y^XM
MJ9SQ=E>4XW@7'3KX2%:JL0J-9X2I[2/LU3Y_:2HRM3]_F@VM)PFHRBU)?0&@
M0ZE:Z'HUOK,RW&KP:780ZI<*=RS:A%:Q)>2AN-P:X60[L#.<X&<#XK%RH3Q>
M)GA8.GAI5:CI1>\:;FW!/TC9'Z=ET,72R_ TL=457&T\/1CB)K:5:-.*JR7D
MYJ3N:U<YV'G^JIJ@^('AF*#5=7ATJZTC7;R]L(6@_L][G2IM%CLDDW6C,BRI
M?W>]?-!?RUVE=AS[&'>'638YSP]&6)IU\/"G4ES>T4*L:[G9*:B^5TX6?([7
M=[W1\YBXXQ<1Y5"GB\13P57#8NI5I0Y/8.I0GA8TE)NFW'G5:IS+G3ERIQMR
MLP-%UWQI<:IH-O?6*QZ//XU\:6,FJ"^WW=Y8V'_"9?V;:76E#2XQ96L365D(
MYQ=.7^QP$@^><=>(PF54\/BYTJ[EBH8+!5(TN1*$*E3ZG[64*OMFZDVJDW*'
MLER\T^E.YY^!Q^?5,7E]+$891P4\SS.E*NJMZLZ-'^TOJ\*F'^KQ5*G%TJ2C
M459N7LZ;=_:M%'0-;UNXC^(#SZE=-?:='XM.F6[:E%<O MGJ>JQ6$D>C#1H&
ML#%#!9K&QO+L3*X8A=X TQ>%PE.>31A1C&A6^J>UE[-P4G.E1=1.M[>:G>4J
MG-:G3Y&K:V,,NQV85*?$<ZF)G+$8;^T/84W6C-P5*OB8T6L,L+3=+EA"DH-U
MJ_M4^:RN'A[Q'XHT[0/%]SJBZE=ZAIKZ=9Z'I6H^5J&IRZI?Z? 8'6;3M-ME
MNM-N[Z\MC&$69XEAN0[C9LC>+P67UL9EM/#RI4Z-=5)UZM/FITHTJ=22DK5:
MM1QJTZ<)<UW",FX.,7?FE.69GF^%RW.ZN+C7KXG".C2PN'K*-:O*O5H0<'S4
M*%%5*%:K5I\BBIRIJ-52DG%P@^77?%>H>#-,A1-6MO$UKXEL?#^K?9XH]&OK
MZ*,NR7\)U.TDCL([ZP:SNBSPE8VG>+JA%*.$RZAF>(DW2E@)X:IB**E*5:%-
MNR]G+V4XRFZ,U.FK23ERQGL[CGF&<XK(\)3C'$4LUI8ZE@\2X0CAJM6,6W[:
M'MZ4X4HXBE[*LVX.,.>5/>+12U;4_%VFZIX#TS7-8DMFGT2Y?Q!<V>HVVE6[
MZA'J6EQ++Y_]AW4=[<QVDT_^BQQV:3$2.KQ* *TP]#+:N&S>OA<,I>SKQ6'A
M.G*K.-)TZS?N_6*;A'FC&]1NJX>ZFI-W>6+Q6=87&<.X3'XUTO:86I+&5*=:
MG0A*O&MAXI\_U2I&K-4YSM1C'#QJOFDI022-G6_$6LVVLZGH=K<WRZC-XT\'
M-I%K'9/)YOA:6#P^VO2PRBV,;6*/#KGGRL^8CO!9=T8/-A<#A98;#XJI&'L(
M8+&>VFZB7+BHO$+#QE'F4E4:=#V<4K3WLTIV[L?F>/I8W%8"C4J+%3S/+?JU
M-4F^; ..#>,E&7(XNE%QQ?M9N5Z;NN:+<+WF.LVFL?$25=7UJ>#3]"ANM&M9
MS;O9V]W?VFI7<AM%6S5I&@FM+=(E+OM5RK;BV1E'ZI/#9-!X:C&=7$2C7G'F
M4Y0ISI17.W4:BI*<G)J,;M)JR1N_K]#&\2SCC,3.GA\'"IA:<U!TX5:M/$3E
M[-*DI2<)4X1A%RERIM-2YDRIJ6KW8O\ 2(-9\0ZQX:TUO#6DWUG>:;:P%]7U
MZ:2X74;6YFGTN\0RVT*:>\=DL:><;^0E9!&%CTH8:DJ&(EA<'1QM>.)K4YPJ
M3E^YP\5%TIQC&K2=IR=12JMR4/9Q5X\UY98K&5UB<'3QN8XC*\++!8>K2J4*
M<+XC%RE-5J<Y3P]>/-3BJ+A048NHZLW:?(E"]-JVHVOQ(M=.EO[RZTZ_MECM
M;"QE@6/3GCTVYN)9-9T^733)-9S20[X]1M[Q=D[Q6LD84G?E##T)Y)4K1I0I
MUZ$KRJ34KU4ZD8I49JJHJ<5)*5&5)W@I58RNM.B>,Q-'B:EA9XB=;#8BG:G1
MI2@E0<:,YREB:,J+G*G-Q;AB:=:*C5<*$H6=Y>FUX9]0% !0 4 % !0 4 5[
MNU@O;6YLKI/,MKNWFM;B+++O@N(VBE3<I!7=&S#((//%73J3HU*=6F^6=*49
M1?:46G%_)I&=:C3KT:M"K'FI5H2ISCJKPG%QDKJS5TVM-3Q_2?A#8^"="\71
M>"+_ %"+Q!KNF7%K97^I741:R94F:UAMY+:VC\@>9(,S%7<,JN"-N*^GQ7$]
M?-L9E<LXI4Y8+ U8RG2I0:YXWC[1R4I2YFXQ^%-1W5M3X7 \#87AW+<]I\.8
MBM2S/,Z$X4JU>HG[&2C+V<8.$(\B4I:S:E--*5_=2.8\!^"OBEI7@#QGH^J:
MI)::UJ2,OAM)]5%[-82^3(MU(M]#),+1;HM&J;)"8W5I<(S9/H9UFO#F)SK*
ML5A<*I8+#N/UI1H^SC52DG%>S:AS."OS724E:-VD>1PSD'&>"X9S_ X_'.EF
M6+4OJ'/B/;2HRY&IR]M%S]FJKMR6DW3DG4Y8R>MGX?\ PP\07'@37?"?Q*GN
M9;;5-0BGLK6/4TO+S3EMS',;B&]5IHXC)=1HXB!D3Y'+K^^8'/.\_P ##.<'
MF7#U.-*>&I.,Y.E[.%1N\>5T[1>D'RN7NO;E?NQ9IPQPAFE7AG,LCXPK3K4\
M974Z=-8CVM6C&'++GC6]])RJ14XPO.*L^9-SDCUCP5X*T;P%HHT+1/M36QNI
M;R:>]E2:ZN+J98HWEE:**.,8B@A0*D: ",<$DD_.9MFV+SC%O&8SD53EC!1A
M'EA&,;M))MO=MMMMW;UM9'VW#_#^7\,Y?'+<M4_8*<JLI59*=2=2=DY2:48_
M#&,4HQBDHK2]V^NKS#VPH * "@ _I^E !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
